Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 1:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 1,227 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Fusion Clear all
Active, not recruiting Phase 1 Interventional

Dendritic Cell/AML Fusion Cell Vaccine Following Allogeneic Transplantation in AML Patients

NCT03679650
View directory record Official record
Conditions
Acute Myelogenous Leukemia
Interventions
DC/AML fusion cells
Biological
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 21, 2026, 1:22 AM EDT
Completed Not applicable Interventional Results available

Measuring Dysphagia After ACDF Surgery Through A Novel Wearable Sensor

NCT04921800
View directory record Official record
Conditions
Cervical Spine Fusion
Interventions
Anterior Cervical Discectomy & Fusion, Application of ADAM mechanoacoustic skin sensor
Procedure · Device
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 88 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 9, 2025 · Synced Oct 21, 2026, 1:22 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Tranexamic Acid in Spinal Fusion Surgery

NCT03425799
View directory record Official record
Conditions
Spinal Fusion
Interventions
Sodium Chloride 0.9% Inj, Tranexamic Acid
Drug
Lead sponsor
Exela Pharma Sciences, LLC.
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
4
States / cities
Long Beach, California • Los Angeles, California • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2021 · Synced Oct 21, 2026, 1:22 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Trial Assessing the Impact on Facial Skin Quality, Hydration, and Skin Barrier of Three (3) Hydrafacial Treatments in Adults of All Skin Types.

NCT05932732
View directory record Official record
Conditions
Cutis Laxa Facialis, Xeroderma
Interventions
HydraFacial Syndeo System, ReGen-GF, HydraFacial Elite MD System
Device · Drug
Lead sponsor
Austin Institute for Clinical Research
Network
Eligibility
30 Years to 55 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
2
States / cities
Houston, Texas • Pflugerville, Texas
Source: ClinicalTrials.gov public record
Updated Oct 24, 2024 · Synced Oct 21, 2026, 1:22 AM EDT
Recruiting No phase listed Observational

The Objective of the Protocol is to Generate Real World Evidence (RWE) Supporting the Safety, Performance, and Health Economics of Using the Regulatory Approved and Commercially Available EARP Interbody System Used During Lumbar Interbody Fusion (LIF) Procedures With the EARP Nerve Cuff Electrode

NCT07020000
View directory record Official record
Conditions
Transforaminal Lumbar Interbody Fusion Surgery
Interventions
Device: Nerve Cuff and Retractor System
Device
Lead sponsor
Retropsoas Technologies, LLC
Industry
Eligibility
22 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
5
States / cities
Jacksonville, Florida • St Louis, Missouri • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 21, 2026, 1:22 AM EDT
Terminated Phase 3 Interventional Results available

SPRING: Safety, Efficacy, Pharmacokinetics of tipRanavir/r IN Race/Gender HIV+ Patients Randomized to TDM or SoC

NCT00440271
View directory record Official record
Conditions
HIV Infections
Interventions
tipranavir, ritonavir, Optimized Background Regimen (OBR)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
16
States / cities
Washington D.C., District of Columbia • Clearwater, Florida • Fort Lauderdale, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2014 · Synced Oct 21, 2026, 1:22 AM EDT
Terminated Phase 1 Interventional

Vaccine Therapy in Treating Patients With Acute Myeloid Leukemia

NCT00100971
View directory record Official record
Conditions
Leukemia
Interventions
autologous tumor cell vaccine, therapeutic autologous dendritic cells, tumor cell-derivative vaccine therapy
Drug · Procedure
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 4, 2013 · Synced Oct 21, 2026, 1:22 AM EDT
Terminated Phase 1 Interventional Results available

Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies

NCT02483000
View directory record Official record
Conditions
Burkitt Lymphoma, CD20-Positive Neoplastic Cells Present, Diffuse Large B-Cell Lymphoma, Indolent Non-Hodgkin Lymphoma, Mantle Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory Mature B-Cell Non-Hodgkin Lymphoma
Interventions
Anti-CD20 B9E9 scFv-Streptavidin Fusion Protein, Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Clearing Agent, Cytarabine, Etoposide, Indium In 111-DOTA-Biotin, Laboratory Biomarker Analysis, Melphalan, Peripheral Blood Stem Cell Transplantation, Pharmacological Study, Yttrium Y 90-DOTA-Biotin
Biological · Procedure · Drug + 2 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Oct 21, 2026, 1:22 AM EDT
Terminated No phase listed Observational

A Multicenter Prospective Registry for the Management of Degenerative Spine Disorders

NCT02802033
View directory record Official record
Conditions
Degenerative Diseases, Spinal Cord
Interventions
Not listed
Lead sponsor
AO Innovation Translation Center
Other
Eligibility
18 Years and older
Enrollment
908 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
5
States / cities
Los Angeles, California • Atlanta, Georgia • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 21, 2026, 1:22 AM EDT
Not yet recruiting Phase 2Phase 3 Interventional

IO Vancomycin Spine

NCT06748144
View directory record Official record
Conditions
Lumbar Fusion Surgery
Interventions
Intraosseous Vancomycin, Intravenous Vancomycin
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 25, 2026 · Synced Oct 21, 2026, 1:22 AM EDT
Completed Phase 4 Interventional Results available

Intrathecal Morphine Versus Epidural Extended Release Morphine for Pediatric Patients Undergoing Spinal Fusion

NCT00880607
View directory record Official record
Conditions
Pain Management, Spinal Fusion, Scoliosis
Interventions
Intrathecal morphine, Extended Release Epidural Morphine
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
8 Years to 17 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 22, 2020 · Synced Oct 21, 2026, 1:22 AM EDT
Completed Phase 1 Interventional

A Phase I Study of the Safety and Pharmacokinetics of Recombinant Human CD4 Immunoglobulin (rCd4-IgG) Administered by Intravenous Bolus in Patients With AIDS and AIDS Related Complex

NCT00000675
View directory record Official record
Conditions
HIV Infections
Interventions
CD4-IgG
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
Stanford, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 21, 2026, 1:22 AM EDT
Completed Phase 2 Interventional Results available

A Study of AUY922 in Non-small-cell Lung Cancer Patients Who Have Received Previous Two Lines of Chemotherapy.

NCT01124864
View directory record Official record
Conditions
Non-small-cell Lung Cancer
Interventions
AUY922
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
4
States / cities
Los Angeles, California • Rockville, Maryland • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2016 · Synced Oct 21, 2026, 1:22 AM EDT
Completed Phase 2 Interventional

A Study Comparing the Efficacy and Safety of Once-Daily Fuzeon (Enfuvirtide) Dosing Versus the Currently Recommended Twice-Daily Dosing in Human Immunodeficiency Virus-Type 1 (HIV-1) Infected Patients

NCT00089492
View directory record Official record
Conditions
HIV Infections
Interventions
Optimized Background ARVs, enfuvirtide [Fuzeon]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
16 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
21
States / cities
Hobson City, Alabama • Fountain Valley, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 21, 2026, 1:22 AM EDT
Active, not recruiting No phase listed Observational

Observational Study to Evaluate the STALIF® C FLX, STALIF® M FLX, STALIF® L FLX Cages and FORTOS-C®

NCT06876311
View directory record Official record
Conditions
Degenerative Cervical Disc Disease, Degenerative Lumbar Diseases
Interventions
Anterior Cervical Interbody Fusion, Anterior lumbar Interbody Fusion, Lateral Lumbar Interbody Fusion
Device
Lead sponsor
Silony Medical GmbH
Industry
Eligibility
21 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
San Ramon, California
Source: ClinicalTrials.gov public record
Updated Mar 14, 2025 · Synced Oct 21, 2026, 1:22 AM EDT
Terminated Phase 1 Interventional

Phase 1, Dose-Escalation Study of IGN002 in NHL Subjects

NCT02519270
View directory record Official record
Conditions
Non-Hodgkin Lymphoma
Interventions
IGN002
Biological
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
Santa Monica, California • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 11, 2022 · Synced Oct 21, 2026, 1:22 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Alefacept in Patients With Severe Scalp Alopecia Areata

NCT00167102
View directory record Official record
Conditions
Alopecia Areata
Interventions
Alefacept
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 22, 2019 · Synced Oct 21, 2026, 1:22 AM EDT
Not listed No phase listed Observational

Retrospective, Multicenter Clinical Evaluation of Health Economic Drivers and Complications for Two Lumbar Fusion Procedures

NCT02171169
View directory record Official record
Conditions
Spinal Stenosis, Spondylolisthesis, Degenerative Disc Disease (DDD)
Interventions
Not listed
Lead sponsor
Baxano Surgical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
3
States / cities
Fullerton, California • Waterford, Michigan • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 3, 2014 · Synced Oct 21, 2026, 1:22 AM EDT
Enrolling by invitation No phase listed Observational

Perioperative Sleep Quality and Postoperative Pain Outcomes

NCT06054802
View directory record Official record
Conditions
Surgery, Pain, Sleep, Spinal Fusion
Interventions
eCAP
Device
Lead sponsor
Grant Heydinger
Other
Eligibility
10 Years to 18 Years
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 21, 2026, 1:22 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Adjacent Segment Mechanics in Cervical Arthrodesis Patients

NCT03028402
View directory record Official record
Conditions
Intervertebral Disc Degeneration
Interventions
C5-C6 arthrodesis
Procedure
Lead sponsor
University of Pittsburgh
Other
Eligibility
21 Years to 60 Years
Enrollment
106 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 6, 2025 · Synced Oct 21, 2026, 1:22 AM EDT
Completed No phase listed Observational

Studying Genes in Samples From Younger Patients With Acute Megakaryoblastic Leukemia

NCT01642069
View directory record Official record
Conditions
Childhood Acute Megakaryocytic Leukemia (M7), Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies
Interventions
laboratory biomarker analysis
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 30 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Monrovia, California
Source: ClinicalTrials.gov public record
Updated May 18, 2016 · Synced Oct 21, 2026, 1:22 AM EDT
Recruiting No phase listed Observational

Clinical and Radiological Outcomes of Posterior Cervical Fusion Supplemented With Interfacet Spacers

NCT04041583
View directory record Official record
Conditions
Cervical Fusion
Interventions
Cervical Interfacet Spacers
Device
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 21, 2026, 1:22 AM EDT
Completed Not applicable Interventional

Interbody Spacers With map3® Cellular Allogeneic Bone Graft in Anterior or Lateral Lumbar Interbody Fusion

NCT02628210
View directory record Official record
Conditions
Spondylosis, Spondylolisthesis, Degenerative Disc Disease
Interventions
map3® Cellular Allogeneic Bone Graft
Other
Lead sponsor
RTI Surgical
Industry
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
3
States / cities
Niagara Falls, New York • Williamsville, New York • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 24, 2021 · Synced Oct 21, 2026, 1:22 AM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Participants With Inhibitors Undergoing the First ITI Treatment (verITI-8 Study)

NCT03093480
View directory record Official record
Conditions
Hemophilia A With Inhibitors
Interventions
rFVIIIFc
Biological
Lead sponsor
Bioverativ, a Sanofi company
Industry
Eligibility
Male only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
12
States / cities
Orange, California • Aurora, Colorado • Washington D.C., District of Columbia + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2022 · Synced Oct 21, 2026, 1:22 AM EDT